Pemetrexed as Maintenance Therapy for Advanced, Non-Squamous, Non-Small Cell Lung Cancer (NSCLC) [Internet].

About 2,600 new cases of lung cancer are diagnosed each year in Norway, of which 80% are classified as non-small cell lung cancer (NSCLC). Of these, about 75% have locally advanced or metastatic disease at the time of diagnosis. Palliative chemotherapy is the standard treatment for patients in NSCLC stages IIIB-IV who cannot receive curative treatment and whose performance status is good (PS 0-2). The five-year survival rate for patients in these stages is low at about 1%.

http://ift.tt/2rmDZCn